Traveler’s Diarrhea - Pipeline Insight, 2024

Traveler’s Diarrhea - Pipeline Insight, 2024

DelveInsight’s, “Traveler’s Diarrhea - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Traveler’s Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Traveler’s Diarrhea: Understanding

Traveler’s Diarrhea: Overview

Travelers’ diarrhea is a common ailment in persons traveling to resource-limited destinations overseas. Estimates indicate that it affects nearly 40% to 60% of travelers depending on the place they travel, and it is the most common travel-associated condition. Bacterial, viral, and parasitic infections can cause symptoms, though bacterial sources represent the most frequent etiology. While travelers’ diarrhea is typically a benign self-resolving condition, it can lead to dehydration and, in severe cases, significant complications.

Traveler's diarrhea is a prevalent gastrointestinal illness affecting a significant percentage of international travelers, with estimates suggesting that 20-50% of travelers may develop diarrhea depending on the region visited. The condition is most common in travelers from industrialized nations journeying to developing or less industrialized regions like Latin America, Africa, the Middle East, and Asia, excluding Japan. Risk factors for traveler's diarrhea include compromised immune systems, younger age, and the use of acid blockers. The primary bacterial causes include enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni, Shigella, and Salmonella species, while norovirus and rotavirus are common viral sources. Giardia intestinalis is the predominant parasitic cause, with Cryptosporidium and Entamoeba histolytica also implicated. Traveler's diarrhea can affect individuals regardless of prior exposure, with no immunity against future occurrences. The condition is more prevalent in warmer climates with poor sanitation and food handling practices, emphasizing the importance of preventive measures like safe water consumption and food preparation to reduce the risk of infection.

Traveler's diarrhea manifests with a range of symptoms that can significantly impact individuals during their travels. Common signs and symptoms include an abrupt onset of diarrhea, often accompanied by fever, nausea, and vomiting. Bloating and an urgent need to have a bowel movement are also typical indicators of traveler's diarrhea. These symptoms can vary in severity and may lead to dehydration, especially in warm climates. It is essential for travelers to be aware of these signs and symptoms to promptly address the condition and prevent complications, particularly in high-risk regions where traveler's diarrhea is prevalent.

Treatment and management of traveler's diarrhea focus on alleviating symptoms, preventing dehydration, and addressing the underlying infection. In mild cases, rest and oral rehydration solutions containing water and salts are essential to replace lost fluids and electrolytes. Over-the-counter medications like bismuth subsalicylate (Pepto-Bismol) can help reduce the duration and frequency of diarrhea. Anti-motility agents like loperamide provide temporary relief by slowing down bowel movements, but they are not recommended for certain individuals. Antibiotics may be prescribed for severe cases with persistent symptoms, especially if there is a fever or blood in the stool. It is crucial to avoid dehydration by staying hydrated with safe liquids and avoiding caffeine, alcohol, and dairy products. Prevention strategies, such as practicing good hygiene, consuming safe food and water, and seeking medical attention if symptoms worsen, are vital components of managing traveler's diarrhea effectively.

""Traveler’s Diarrhea - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s Diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Traveler’s Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler’s Diarrhea.

Traveler’s Diarrhea Emerging Drugs Chapters

This segment of the Traveler’s Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Traveler’s Diarrhea Emerging Drugs

• IMM124E: Immuron

IMM-124E is a first-in class, oral polyclonal antibody therapy developed to target the endotoxin lipopolysaccharide (LPS) and other pathogenic bacterial components in the human gastrointestinal tract reducing LPS-related inflammation and systemic translocation. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Traveler’s Diarrhea.

Further product details are provided in the report……..

Traveler’s Diarrhea: Therapeutic Assessment

This segment of the report provides insights about the different Traveler’s Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Traveler’s Diarrhea

There are approx. 4+ key companies which are developing the therapies for Traveler’s Diarrhea. The companies which have their Traveler’s Diarrhea drug candidates in the most advanced stage, i.e. Phase II include, Immuron.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Traveler’s Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Traveler’s Diarrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Traveler’s Diarrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s Diarrhea drugs.

Traveler’s Diarrhea Report Insights

• Traveler’s Diarrhea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Traveler’s Diarrhea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Traveler’s Diarrhea drugs?
• How many Traveler’s Diarrhea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traveler’s Diarrhea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Traveler’s Diarrhea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Traveler’s Diarrhea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Immuron
• Scandinavian Biopharma
• Sigmoid Pharma

Key Products

• IMM124E
• ETEC vaccine
• Research programme oral vaccines